Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Eribulin mesylate in Leiomyosarcoma: NCT06957431 Clinical Landscape Report 2026
15 October 2026
NCT06957431 clinical landscape for Leiomyosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HMBD-501 in Locally Advanced Unresectable Breast Carcinoma: NCT06956690 Clinical Landscape Report 2026
15 October 2026
NCT06956690 clinical landscape for Locally Advanced Unresectable Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and developm…
9 min read
Doxorubicin Hydrochloride in Muscle Invasive Bladder Carcinoma: NCT06960577 Clinical Landscape Report 2026
15 October 2026
NCT06960577 clinical landscape for Muscle Invasive Bladder Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Fludarabine Phosphate in Locally Advanced Melanoma: NCT06961357 Clinical Landscape Report 2026
15 October 2026
NCT06961357 clinical landscape for Locally Advanced Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Axitinib in Metastatic Renal Cell Carcinoma: NCT06962787 Clinical Landscape Report 2026
15 October 2026
NCT06962787 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Metastatic melanoma: NCT06961786 Clinical Landscape Report 2026
15 October 2026
NCT06961786 clinical landscape for Metastatic melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nivolumab in Metastatic Triple-Negative Breast Carcinoma: NCT06963905 Clinical Landscape Report 2026
15 October 2026
NCT06963905 clinical landscape for Metastatic Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Romidepsin in Bladder Cancer: NCT06963346 Clinical Landscape Report 2026
15 October 2026
NCT06963346 clinical landscape for Bladder Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BCMA CAR-T Cell(Xuzhou Medical University) in Multiple Myeloma: NCT06963866 Clinical Landscape Report 2026
15 October 2026
NCT06963866 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
DCC-2812 in Metastatic Renal Cell Carcinoma: NCT06966024 Clinical Landscape Report 2026
15 October 2026
NCT06966024 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
DEBIO-1562M in Acute Myeloid Leukemia: NCT06969430 Clinical Landscape Report 2026
15 October 2026
NCT06969430 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lutetium (177 Lu) Vipivotide Tetraxetan in Metastatic Renal Cell Carcinoma: NCT06964958 Clinical Landscape Report 2026
15 October 2026
NCT06964958 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.